HSBC upgrades UBTech to Buy, saying humanoid robot mass production is faster than expected

Overview

This report is HSBC's company research and rating adjustment note on humanoid robots and embodied AI, with UBTech as the main coverage name and UniTree as the primary comparison. The report argues that humanoid robot mass production is accelerating, and that government-supported data collection scenarios were an important driver of UBTech's 2025 shipments. Industrial-grade full-size embodied robots should help improve UBTech's revenue mix, gross margin, and operating leverage.

Core views

HSBC's core view is that UBTech and UniTree represent two different paths. UBTech is positioned around industrial-grade full-size embodied humanoid robots, with higher technical barriers and stronger suitability for industrial scenarios, and its ASP is also materially higher than UniTree's. UniTree is positioned around mid-sized, consumer-level, and demonstration-oriented products, with lower prices and faster commercialization, and it already reached net profit breakeven in 2025. For UBTech, faster-than-expected mass production progress, stronger orders from government data collection sites, and real-world data from automotive and manufacturing customers support HSBC's upward revisions to shipment, revenue, gross margin, and net profit forecasts, leading to the Buy upgrade.

Analysis framework

The report compares UBTech and UniTree across product positioning, ASP, customer structure, R&D expense ratio, shipment volume, accounts receivable days, capacity, revenue structure, gross margin, and operating leverage, and then re-prices UBTech using a target P/S valuation approach. The valuation benchmark references Tesla's average forward P/S over the past year, with a one-standard-deviation discount applied because of UBTech's potential placement risk.

Methodology notes

• Relative valuationTarget P/S valuation

  Base the valuation on 2027e sales, apply a 9.7x target P/S multiple, and derive the target price using the RMB/HKD exchange rate.

  HSBC believes Tesla is comparable because Optimus robots and UBTech Walker are both full-size industrial humanoid robots, but it applies a one-standard-deviation discount to Tesla's forward P/S average because of UBTech's potential placement risk.

• Company comparisonProduct and commercialization path comparison

  Compare UBTech and UniTree across product positioning, pricing, customer structure, R&D investment, shipments, and collections quality.

  UBTech emphasizes industrial scenarios and full-size embodied capabilities, while UniTree emphasizes lower-priced, mid-sized, consumer-level products; the two differ significantly in ASP, customer prepayment characteristics, R&D expense ratio, and cash conversion.

• Earnings forecastShipment and margin upgrades

  Upgrade revenue, gross margin, and net profit forecasts based on humanoid robot shipments, ASP changes, product mix, and scale effects.

  HSBC raised UBTech's 2026 humanoid robot shipment forecast to 4k units and expects the higher share of full-size embodied robot revenue to lift consolidated GPM to 43.6% in 2026.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• UBTech (9880 HK)

  Core covered company and the subject of the rating upgrade

  Strengths

  Focused on industrial-grade full-size embodied humanoid robots, with a higher ASP and real-world data from government, automotive, and manufacturing customers; capacity has already exceeded an annualized 6k units and is being raised toward 10k units.

  Weaknesses

  Still loss-making, with long DSO and significant cash flow pressure; it has already completed six placements since listing.

  Comparison

  Compared with UniTree, UBTech commercializes more slowly and has weaker cash conversion, but its industrial application value and technical barriers are higher.

  Risks

  Potential placements, slower order growth, test collaborations that fail to convert into actual orders, competitive pressure on margins, and collection and receivable impairment risk.

• UniTree

  Primary comparable company and a catalyst for sector re-rating

  Strengths

  Mid-sized and consumer-level humanoid robots have a lower ASP and lower R&D expense ratio; it shipped about 5.5k units in 2025 and achieved net profit breakeven.

  Weaknesses

  Its products are more oriented toward demonstration and consumer-level scenarios, and the report believes its industrial full-size embodied capability and factory-scenario suitability are weaker than UBTech's.

  Comparison

  Compared with UBTech, UniTree commercializes faster and has better cash conversion, but its ASP and industrial-scenario technical barriers are lower.

  Risks

  The low-price strategy may intensify competition and could also压低 industry ASP and margin expectations.

• Humanoid robots sector

  Theme investment and supply-chain mapping

  Strengths

  Global shipments are growing rapidly, government data collection sites and industrial applications are driving mass production, and technologies such as dexterous hands and VLA training are continuing to evolve.

  Weaknesses

  The industry is still early-stage, and commercialization, cost reduction, conversion of real orders, and the path to profitability still need to be proven.

  Comparison

  The industrial-grade full-size route emphasizes technical barriers and scenario data, while the consumer-level low-price route emphasizes fast shipments and market education.

  Risks

  More new entrants, slower-than-expected cost declines, shipment volatility, deteriorating collection quality, and valuation volatility.

Key data

• Global humanoid robot shipments18k units in 2025, 2.3k units in 2024The report believes mass production is accelerating.
• 2026 global humanoid robot base-case shipment forecast31k unitsHSBC base-case forecast.
• UBTech 2025 full-size humanoid robot shipmentsapproximately 1,076 to 1,079 unitsHigher than previous expectations, mainly concentrated in 2H25.
• UBTech 2026 humanoid robot shipment forecast4k units, versus the prior forecast of 2.6k unitsThe upgrade reflects stronger-than-expected orders from government data collection sites.
• UBTech 2026 full-size embodied robot revenue forecastRMB2.6bn, up 215% year over yearExpected to account for 69% of total revenue.
• UBTech humanoid robot ASPapproximately RMB760kMaterially higher than UniTree's.
• UniTree humanoid robot ASPapproximately RMB168kThe lower ASP supports faster commercialization.
• UBTech 2025 average days sales outstanding268 daysMaterially higher than UniTree's.
• UniTree 2025 average days sales outstanding19 daysCustomers are mainly research institutions, universities, and distributors, with a higher prepayment ratio.
• UBTech 2026 consolidated GPM forecast43.6%, up 5.9 percentage pointsBenefiting from a higher revenue mix of high-margin full-size humanoid robots.
• UBTech net profit breakeven expectation2027eScale effects and improved operating leverage are key assumptions.
• Target price and ratingBuy, HKD126.00Upgraded from Hold to Buy, and the target price was raised from HKD124.00 to HKD126.00.

Impact & implications

The report's investment implication is broadly positive: if UBTech can convert testing demand from government data collection, automotive, and manufacturing customers into sustained orders, its industrial-grade full-size humanoid robot business could enter a stage of rapid revenue growth and margin improvement, prompting the market to re-rate the humanoid robot supply chain. At the same time, UniTree's low-price strategy and potential A-share IPO could increase sector attention, but may also intensify price and valuation competition. For UBTech shares, the key support for the upgrade is faster-than-expected mass production, upward revisions to revenue forecasts, and still-meaningful 16% upside to the target price.

Risks

• Weaker orders from government data collection sites could cause near-term robot shipments to fall short of expectations.
• Slower-than-expected commercialization could weigh on medium- to long-term robot shipments.
• Testing partners may fail to convert into actual orders, resulting in humanoid robot revenue growth below expectations.
• Slower-than-expected cost reduction from suppliers could lead to humanoid robot gross margins below expectations.
• More participants entering the market and starting deliveries would force UBTech to compete directly for new orders, which could hurt margins.
• Intensifying competition in legacy businesses such as consumer, education, logistics, and sector-customized robots could pressure ASP.
• R&D or sales expenses above expectations could delay net profit breakeven.
• Operating leverage weaker than expected could further delay the profitability inflection point.
• Potential equity placements could pressure the share price.
• If accounts receivable collection does not improve or government clients delay payment, additional receivable impairment could arise.

What to watch

• Progress on UBTech's new product launches in 2Q.
• Execution of large new orders from government and commercial customers.
• Whether demand from government data collection sites remains sustained.
• Execution progress toward the 2026 4k-unit shipment target.
• The decline in ASP and BOM costs for full-size embodied humanoid robots.
• Whether consolidated GPM can improve to around 43.6%.
• Improvement in days sales outstanding and operating cash flow.
• Whether any new equity placements or financing actions occur.
• Progress in UniTree's A-share IPO and its impact on humanoid robot sector valuations.
• Advances in dexterous hands, VLA models, and multi-robot collaboration.